Glaukos (GKOS) Stock Price
$98.5 0.2%
to add to portfolio
AI Score
-
Alternative
8 -
Fundamental
8 -
Technical
3
Our AI score evaluates a company's performance on a scale from 0 to 10 by analyzing alternative data points — web traffic, app downloads, job postings, etc - along with financial health and technical signals. Scores below 4 project bearish performance, while scores above 6 project bullish performance.
Sign up to get access to more historical data and insights on Glaukos, AI stock picks, stock alerts and much more.
GKOS AI Stock Analysis
AI stock analysis for GKOS is missing at the moment.
Our AI stock analysis reviews financial data, technical analysis, and alternative data insights to project stock performance. For example, analyzing a company like Glaukos (GKOS) provides a clear summary of future projections. Gain the edge you need to make confident, data-driven investment decisions.
Sign up and become a member to get access to AI stock analysis.
Sign up
Glaukos (GKOS) Price Prediction
Based on a combination of financial analysis, technical indicators, and insights from alternative data, we predict that the stock price of Glaukos (GKOS), currently trading at $98.5, will... Sign up to access price prediction.
Disclaimer:
This prediction is provided for informational purposes only and does not constitute financial advice. Market conditions are subject to change, and past performance is not indicative of future results. Please conduct your own research or consult a professional before making investment decisions.
About GKOS
-
Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases.
-
Symbol
GKOS
-
Market
NYSE
-
Industry
Medical - Devices
-
Market Cap
5.6B
Similar Stocks
 |
Abbott Laboratories ABT |
$131.7 0.2% |
6 |
 |
Boston Scientific BSX |
$103.2 0.3% |
6 |
 |
Edwards Lifesciences EW |
$76.14 0.9% |
6 |
 |
Medtronic MDT |
$89.78 0.6% |
6 |
 |
Stryker SYK |
$390.9 0.1% |
6 |
News
GKOS Alternative Data
Web Traffic
Glaukos receives an estimated 20498 monthly visitors to glaukos.com.
-
Web Traffic
20498
-
Change from Previous Month
5.6%
-
3 Month Change
9.3%
-
YoY Change
9.3%
Facebook Engagement
Glaukos has engaged 296 users via their Facebook Page over the last 7 days.
-
Facebook Engagement
296
-
Daily Change
0%
-
1 Month Change
30.5%
-
3 Month Change
92.2%
-
YoY Change
92.2%
Instagram Followers
Glaukos has 3,474 Instagram Followers on its main Instagram account, up by 1.2% over the last month.
-
Instagram Followers
3474
-
Daily Change
0.1%
-
1 Month Change
1.2%
-
3 Month Change
5.3%
-
YoY Change
5.3%
LinkedIn Followers
30,887 are following Glaukos on LinkedIn, up by 2.7% over the last month.
-
LinkedIn Followers
30887
-
Daily Change
0.1%
-
1 Month Change
2.7%
-
3 Month Change
6.8%
Job Postings
Glaukos currenly has an estimated 27 open job postings.
-
Job Postings
27
-
Daily Change
3.8%
-
1 Month Change
0%
-
3 Month Change
12.9%
-
YoY Change
12.9%
LinkedIn Employees
According to LinkedIn, Glaukos has 952 employees, up by 2.1% over the last month.
-
LinkedIn Employees
952
-
Daily Change
0%
-
1 Month Change
2.1%
-
3 Month Change
5.7%
-
YoY Change
5.7%
Reddit Mentions
Glaukos has been mentioned an estimated 0 times in investment subreddits on Reddit over the last 24 hours.
-
Reddit Mentions
0
-
Daily Change
0%
-
1 Month Change
0%
-
3 Month Change
0%
Twitter Followers
Glaukos has 1,627 Twitter Followers on its main Twitter (also known as X) account, which is up by 0.3% over the last month.
-
Twitter Followers
1627
-
Daily Change
0%
-
1 Month Change
0.3%
-
3 Month Change
0%
-
YoY Change
0%
Business Outlook
According to employee reviews, the business outlook among employees at Glaukos is 89 out of 100 (very bullish).
-
Business Outlook
89
-
Change from Previous Month
0%
-
3 Month Change
1.1%
-
YoY Change
1.1%
News Mentions
Glaukos was mentioned 0 times in the news yesterday.
-
News Mentions
0
-
Daily Change
0%
-
1 Month Change
0%
-
3 Month Change
100%
GKOS Financials
GKOS Key Metrics
-
Total Revenue
$106.7M
-
Net Income
-$18.1M
-
Earnings per Share
-$0.32
-
Free cash flow
-$20.5M
-
EBITDA
-$20.7M
-
EBITDA Ratio
-0.193861
-
Total Assets
$966.2M
GKOS 2-year Revenue & Income
GKOS 2-year Free Cash Flow
GKOS Technicals
GKOS SMA
GKOS RSI
FAQ
What's the current price of Glaukos (GKOS) Stock?
The price of an Glaukos (GKOS) share is $98.5.
What's the market cap of Glaukos?
The current market cap of Glaukos is 5.6B.
Should I buy or sell GKOS?
Multiple alternative data signals suggest that Glaukos stock could offer a buying opportunity at its current level, with a reasonable expectation for positive performance in the mid term.
Is Glaukos a good investment?
Based on an in-depth analysis that encompasses fundamentals, technical analysis, and alternative data insights, it appears to be a favorable time to consider investing in Glaukos stock. The bullish indicators suggest that Glaukos' growth prospects and market position may lead to a positive performance in the foreseeable future.
Is now a good time to buy Glaukos (GKOS) Stock?
Based on an analysis that includes fundamentals, technical analysis, and alternative data insights, it could be a favorable time to consider buying Glaukos stock, given the bullish outlook.
What are some stocks similar to Glaukos (GKOS) that investors often compare it to?
Glaukos (GKOS) is often compared to similar stocks such as Abbott Laboratories, Boston Scientific, Edwards Lifesciences, Medtronic and Stryker.
What is the forecast for Glaukos' stock price in 2026?
Using a mix of financial analysis, technical indicators, and alternative data, we forecast Glaukos' stock price to be around $106.5 in 2026. Starting from the current price of $98.5, this represents a 8.1% change in price, indicating a bullish outlook for the stock.
How to buy Glaukos (GKOS) Stock?
Glaukos stock is available for purchase through numerous brokerage firms, including online platforms. Investors can also buy Glaukos shares via trading apps on their smartphones or by utilizing services like robo-advisors for automated investing.